SCHEMBL8702014

SCHEMBL8702014

O=Cc1ccc(N2CCCC2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.49
MAPT P10636 3/20 0.49
KMT2A Q03164 3/20 0.49
PSMD14 O00487 1/20 0.49
TRIM24 O15164 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.42
KDM4E B2RXH2 3/20 0.42
POLB P06746 1/20 0.40
ALDH1A3 P47895 3/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
ALOX12 P18054 1/20 0.37
CASP1 P29466 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32676141 0.98 ALDH1A1 (0.51) ALDH1A1MAPTKMT2APSMD14TRIM24
SCHEMBL1260268 0.98 ALDH1A1 (0.51) ALDH1A1MAPTKMT2APSMD14TRIM24
SCHEMBL32676230 0.96 ALDH1A1 (0.44) ALDH1A1MAPTKMT2APSMD14TRIM24
SCHEMBL50465 0.89 DPP4 (0.46) ALDH1A1MAPTKMT2APSMD14TRIM24
SCHEMBL31178703 0.84 CA2 (0.36) ALDH1A1MAPTKMT2APSMD14SMN1; SMN2
SCHEMBL1432603 0.82 AOC3 (0.40) ALDH1A1MAPTKMT2APSMD14SMN1; SMN2
SCHEMBL31178618 0.82 ALDH1A1 (0.35) ALDH1A1MAPTKMT2APSMD14SMN1; SMN2
SCHEMBL1555679 0.82 TDP1 (0.51) ALDH1A1MAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL1432800 0.82 ALDH1A1 (0.55) ALDH1A1MAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL31178490 0.81 KDM4E (0.38) ALDH1A1MAPTKMT2APSMD14SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049073-A1 SPECTACLE LENS COMPRISING AN ORGANIC DYE OAKLEY, INC. (US) 2026-02-19 US disclosed
US-20130157191-A1 TONER FOR ELECTROPHOTOGRAPHY AND IMAGE-FORMING METHOD KONICA MINOLAT BUSINESS TECHNOLOGIES, INC. (JP) 2013-06-20 US disclosed
US-5708178-A Thermally stable electro-optic device and method LOCKHEED MARTIN CORPORATION (US) 1998-01-13 US disclosed
US-5561733-A ACCEPTOR-DONOR-ACCEPTOR OR DONOR-ACCEPTOR-DONOR GUEST DIPOLE COMPOUNDS IN A TEMPERATURE-RESISTANCE POLYMER MATRIX LOCKHEAD MISSILES & SPACE COMPANY, INC. (US) 1996-10-01 US disclosed
EP-0493716-A1 Functionalized heteroaromatic compounds for nonlinear optical applications ENICHEM S.p.A. (IT) 1992-07-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049073-A1 SPECTACLE LENS COMPRISING AN ORGANIC DYE STRA6, TCOF1, CLIC1 ALDH1A1 873/4885MAPT 2539/4885KMT2A 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.